Barclays’s Agios Pharmaceuticals AGIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-30,000
Closed -$877K 4830
2024
Q1
$877K Sell
30,000
-30,000
-50% -$803K ﹤0.01% 3223
2023
Q4
$1.34M Buy
+60,000
New +$1.34M ﹤0.01% 3227
2018
Q3
Sell
-27,000
Closed -$2.27M 7086
2018
Q2
$2.27M Hold
27,000
﹤0.01% 2466
2018
Q1
$2.21M Buy
+27,000
New +$2.09M ﹤0.01% 2367
2016
Q4
Sell
-358,400
Closed -$18.9M 6577
2016
Q3
$18.9M Buy
+358,400
New +$15.6M 0.02% 573

Other funds holding AGIO

Barclays's AGIO Position: Q1 2026 in Review

Barclays reduced its Agios Pharmaceuticals (AGIO) stake by 84% in Q1 2026, selling an estimated $7.6M and leaving 52,438 shares worth $1.77M. The position accounts for ﹤0.01% of the portfolio, ranked #2422.

Barclays first reported a position in AGIO in Q3 2013 and has held it in 51 quarters since. The position peaked at $8.72M in Q4 2025. 232 funds tracked by Wall St. Rank hold AGIO as of Q1 2026.

  • Barclays held 52,438 shares of Agios Pharmaceuticals worth $1.77M as of Q1 2026.
  • Barclays sold 267,914 Agios Pharmaceuticals shares in Q1 2026, an estimated $7.6M.
  • Agios Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2422 holding.
  • Barclays first reported a position in Agios Pharmaceuticals in Q3 2013 and has held it in 51 quarters since.
  • Barclays's Agios Pharmaceuticals position peaked at $8.72M in Q4 2025.
  • 232 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.